AstraZeneca

Related Content

The program aims to improve health outcomes, with a focus on increasing awareness of the symptoms and risks of hypertension

Expansion of AstraZeneca’s Flagship Health Equity Program Healthy Heart Africa

June 28, 2024 — AstraZeneca has set out a new ambition for Healthy Heart Africa, its flagship health equity initiative ...

June 28, 2024

Participants saw 35% reduction in LDL cholesterol, signaling the process could offer safe, effective non-prescription use of life-saving drug

News | Cardiovascular Clinical Studies

Study Shows Web App Effective in Determining Access to Statins Without a Prescription

April 9, 2024 — Using a web application to qualify individuals for treatment with a nonprescription statin closely ...

April 09, 2024

$Results from the DELIVER and DAPA-HF Phase III trials demonstrate FARXIGA’s efficacy in heart failure regardless of ejection fraction$

News | Cardiovascular Clinical Studies

FARXIGA Met Primary Endpoint in DELIVER Phase III Trial

May 5, 2022 — High-level results from the DELIVER Phase III trial showed AstraZeneca’s FARXIGA (dapagliflozin) reached a ...

May 05, 2022

News | Coronavirus (COVID-19)

Dapagliflozin Did Not Significantly Reduce Organ Failure or Death in High-Risk Hospitalized COVID-19 Patients

May 18, 2021 — Dapagliflozin (Farxiga), a sodium-glucose co-transporter 2 (SGLT2) inhibitor, did not significantly ...

May 18, 2021

Dapagliflozin (Farxiga) heart failure drug performs very will to improve outcomes for patients with chronic kidney disease.

News | Pharmaceuticals

Dapagliflozin Meets All Endpoints to Treat Chronic Kidney Disease

July 28, 2020 — AstraZeneca's heart failure medication dapagliflozin (Farxiga) significantly reduced the worsening of ...

July 28, 2020

$The U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) from AstraZeneca and granted priority review for dapagliflozin (Farxiga) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF) with and without type 2 diabetes (T2D).$

News

Dapagliflozin Granted FDA Priority Review for Heart Failure With Reduced Ejection Fraction

January 7, 2020 — The U.S. Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) ...

January 07, 2020

The U.S. Food and Drug Administration (FDA) has granted market clearance for AstraZeneca's dapagliflozin (Farxiga) to reduce the risk of hospitalization for heart failure (HF) in adults with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.

Feature | Heart Failure| Dave Fornell, Editor

FDA Clears Dapagliflozin to Reduce Heart Failure Hospitalizations

October 21, 2019 – The U.S. Food and Drug Administration (FDA) has granted market clearance for AstraZeneca's ...

October 21, 2019

Brilinta Monotherapy Reduces Clinically Relevant Bleeding Risk Post-PCI in High-Risk Patients

News | Antiplatelet and Anticoagulation Therapies

TWILIGHT Study Shows Ticagrelor Monotherapy Reduces Bleeding Risk Post-PCI in High-Risk Patients

September 26, 2019 — New data from the Phase IV independent TWILIGHT trial showed Brilinta (ticagrelor) monotherapy ...

September 26, 2019

News | Heart Failure

Farxiga Significantly Reduces Cardiovascular Death and Worsening of Heart Failure

September 9, 2019 — AstraZeneca announced detailed results from the landmark Phase III DAPA-HF trial that showed Farxiga ...

September 09, 2019

News | Heart Failure

Diabetes Drug Effective Against Heart Failure in Wide Spectrum of Patients

March 29, 2019 — The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of ...

March 29, 2019